<DOC>
	<DOCNO>NCT02916537</DOCNO>
	<brief_summary>The purpose study test novel diagnostic Positron Emission Tomography ( PET ) image agent safety biodistribution . The agent bind Prostate Specific Membrane Antigen ( PSMA ) design detect prostate tumor .</brief_summary>
	<brief_title>A Phase 1 Trial Safety Imaging Evaluation CTT1057 , Small Molecule Inhibitor Prostate Specific Membrane Antigen ( PSMA )</brief_title>
	<detailed_description>The sponsor develop PET image agent , CTT1057 , label 18F , base small molecule core target extracellular region PSMA high affinity . Although comparable inhibitor term affinity PSMA , unique class phosphoramidate agent know irreversible PSMA inhibitor . Due irreversible bind PSMA rapid uptake PSMA-expressing prostate cancer cell , accumulation cancer target expect rapid , specific sensitive . Twenty patient enrol parallel two cohort : - ( Cohort A ) Patients prostate cancer prior radical prostatectomy ( N = 5 ) . - ( Cohort B ) Patients evidence metastatic castration-resistant prostate cancer ( N = 15 ) Participants receive single intravenous ( IV ) dose ( 370 MBq , 10 mCi ) CTT1057 first-in-human trial . Combined PET/MR imaging ( prostate + whole body ) perform follow tracer injection . The 5 patient pre-prostatectomy cohort comprise dosimetry/pharmacokinetic ( PK ) cohort establish organ dosimetry PK profile . Patients cohort A undergo plan radical prostatectomy ( plus lymph node dissection ) within 12 week follow CTT1057 PET/MR . Patients cohort B ( metastatic prostate cancer ) option metastatic tumor biopsy follow CTT1057 PET image . The one-time nominal inject dose 370 MBq ( 10 mCi ) . Estimated mass dose 20 µg CTT1057 . Dose volume 3 - 5 mL , inject intravenously bolus injection . Vital sign , adverse event assessment , 12 lead ECGs perform day 1 dosing .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Male patient age ≥18 year old Histologically confirm adenocarcinoma prostate Adequate organ function include : Platelet count &gt; 50,000/mm3 Neutrophil count &gt; 1000/mm3 Serum Cr &lt; 1.5 x ULN estimate GFR &gt; 60 ml/min base upon CockroftGault equation Proteinuria &lt; 1 g/24 hour base upon 24 hour urine collection spot urine protein/creatinine ratio AST ALT &lt; 2.5 x ULN ( &lt; 5 x ULN patient know liver metastasis ) Total bilirubin &lt; 1.5 x ULN ( &lt; 3 x ULN patient known/suspected Gilbert 's disease ) ECOG performance status 0 1 Able provide write informed consent willing comply protocol requirement No contraindication MR include severe claustrophobia , incompatible aneurysm clip cardiac pacemaker For men childbearing potential , use effective contraceptive method trial within 6 month follow radiotracer injection Cohort A ( N = 5 evaluable patient ) : Planned radical prostatectomy within 12 week follow protocol scan No androgen deprivation , antiandrogen therapy , chemotherapy , investigational systemic therapy prior CTT1057 PET image Cohort B : Presence least three distinct metastatic lesion standard image include whole body bone scan + crosssectional image abdomen pelvis obtain within 12 week prior protocol scan Castrationresistant disease define PCWG2 criterion Must remain androgen deprivation therapy duration trial prior bilateral orchiectomy Inadequate venous access per assessment treat health care provider Receipt radioisotope within 5 physical half live prior trial enrollment Prior treatment alpha radiation therapy ( Radium Ra 223 chloride ; Xofigo™ ) previous 60 day Have medical condition circumstance , opinion investigator would significantly decrease chance obtain reliable data , achieve study objective , complete trial . Histologic evidence small cell prostate cancer neuroendocrine differentiation &gt; 50 % biopsy tissue</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>prostate specific membrane antigen</keyword>
	<keyword>prostate neoplasm</keyword>
	<keyword>metastatic prostate cancer</keyword>
	<keyword>prostatic hyperplasia</keyword>
</DOC>